Maine Medicine Weekly Update - Maine Medicine Weekly Update
October 18, 2021  (Plain Text Version)

Return to Graphical Version

 

In this issue:
LEAD STORY
•  FDA Advisory Committee Recommends Moderna, J&J Boosters. What You Need to Know
More COVID Guidance & News
•  Maine CDC Memos: Planning Efforts for Moderna Booster and Pfizer Vaccine for 5-11-year-olds
•  Draft Study Shows Moderna & Pfizer May Be Better Boost for J&J Recipients
•  FDA Schedules Advisory Committee Meeting to Discuss COVID-19 Oral Treatment
•  Federal COVID Vaccine Mandate Rules Have Been Drafted
Maine Health System News
•  Central Maine Healthcare Services, Staffing, Vaccine Mandate, CEO Appointment
Clinical News
•  New Draft Recommendation Statement on Aspirin Use to Prevent Heart Disease and Stroke
•  Top JAMA, JAMA Network, and New England Journal of Medicine Articles
Physician Well Being
•  Using Electronic Health Records to Predict Physician Departure
Webinars
•  Preventing Stimulant Misuse Among College-Aged Students
UPCOMING EVENTS
•  Upcoming Specialty Society Meetings
•  AAP EQIPP Course: Immunizations - Strategies for Success (for RURAL Health Providers)
•  SUPPORT for ME Training and Technical Assistance Initiative
•  SUPPORT For ME Training and Technical Assistance Initiative Webinars on November 3 & December 1
•  Maine Independent Clinical Information Service: MICIS presentations & Academic Detailing
HEALTHCARE EMPLOYMENT OPPORTUNITIES
•  Physician (BC/BE in Family Medicine) - Mt. Abram Regional Health Center, (Kingfield, Maine)
•  Physician (BC/BE in Family Medicine) - Bingham Area Health Center

 

FDA Schedules Advisory Committee Meeting to Discuss COVID-19 Oral Treatment

The U.S. Food and Drug Administration announced an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s request for an emergency use authorization (EUA) for molnupiravir, an investigational antiviral drug to treat COVID-19.

On Nov. 30, the advisory committee will meet to discuss the available data supporting the use of molnupiravir to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who have tested positive for COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

The U.S. Food and Drug Administration announced an upcoming meeting of its Antimicrobial Drugs Advisory Committee (AMDAC) to discuss Merck and Ridgeback’s request for an emergency use authorization (EUA) for molnupiravir, an investigational antiviral drug to treat COVID-19.

On Nov. 30, the advisory committee will meet to discuss the available data supporting the use of molnupiravir to treat mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who have tested positive for COVID-19, and who are at high risk for progression to severe COVID-19, including hospitalization or death.

During the meeting, the committee will hear presentations from the company regarding the data for the antiviral drug. The FDA will also present its perspective regarding the sponsor’s data. There will be an open public hearing during which the public will be given an opportunity to provide comments.

Click here for the FDA media release announcing the meeting

The FDA intends to live stream the AMDAC meeting on the agency’s YouTube page

Preliminary results from a British study released in June also showed promise.